Publications by authors named "Jan G Hatlebakk"

Background: Gastroesophageal reflux disease (GERD) is a common chronic digestive disease that affects people in different communities at different rates. Because of the absence of a validated Arabic tool to assess GERD symptoms, this study aimed to validate and culturally adapt the GERD questionnaire (GerdQ) tool to Arabic speakers.

Methods: Patients referred for pH testing with symptoms suggestive of GERD were recruited.

View Article and Find Full Text PDF

The long-term effects of the transplant dose, its administration route and repeated faecal microbiota transplantation (FMT) on the outcomes of FMT for patients with irritable bowel syndrome (IBS) are unknown. This study included 171 patients (125 females and 46 males): 90 g of donor feces was administered into the large intestine (LI) in 58, into the small intestine (SI) in 57, and into the SI twice (repeated SI) in 56. The patients provided a fecal sample and completed five questionnaires at the baseline and at 2 years after FMT.

View Article and Find Full Text PDF

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), contributes to substantial morbidity. Understanding the intricate interplay between dietary factors and the incidence and progression of IBD is essential for developing effective preventative and therapeutic strategies. This umbrella review comprehensively synthesizes evidence from systematic reviews and meta-analyses to evaluate these complex associations.

View Article and Find Full Text PDF

Background: Previous studies showed that patients with Severe IBS respond better to fecal microbiota transplantation (FMT) than do those with Moderate IBS.

Aims: The present study aimed to determine the effects of the transplant dose, route of administering it and repeating FMT on this difference.

Methods: This study included 186 patients with IBS randomized 1:1:1 into groups with a 90-g transplant administered once to the colon (LI), once to the duodenum (SI), or twice to the distal duodenum twice (repeated SI).

View Article and Find Full Text PDF

Background: Faecal microbiota transplantation (FMT) performed with a proper protocol is a safe treatment for IBS that has high efficacy and durable effects. Females have been reported to respond better than males to FMT. The present study aimed at determining whether increasing the transplant dose or repeating FMT improve the responses of males to FMT.

View Article and Find Full Text PDF

Background: A previous study that introduced a Fecal microbiota transplantation (FMT) protocol with a high efficacy applied a combination of favorable factors.

Aims: The present study aimed to evaluate some of these factors.

Methods: This study included 186 patients with IBS randomized 1:1:1 into transplant administered to the colon (single LI), to the duodenum (single SI), or to the duodenum twice with a 1-week interval (repeated SI).

View Article and Find Full Text PDF

Background And Aims: Per oral endoscopic myotomy (POEM) has become an established treatment for achalasia, but no Scandinavian studies with long-term follow-up exist. This study from a tertiary referral center in Norway investigates the short-, mid-, and long-term feasibility, safety, efficacy, and complications of POEM.

Methods: Prospective data from the first 84 patients who underwent POEM from 2014 to 2019 were analyzed.

View Article and Find Full Text PDF

Fecal microbiota transplantation (FMT) from healthy donors has been shown to improve the symptoms of irritable bowel syndrome (IBS) and changes the profile of the gut microbiota for the recipients. Alternatively, anaerobically cultivated human intestinal microbiota (ACHIM) can be used to manipulate the gut microbiota. The aim of the current study was to compare the efficacy and safety of ACHIM suspension with donor-FMT and placebo (patient's own feces) to treat IBS.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the long-term effects of fecal microbiota transplantation (FMT) for treating irritable bowel syndrome (IBS) over three years.
  • Participants included 125 patients divided into groups receiving different amounts of donor feces and a placebo.
  • Results showed that patients receiving FMT reported significantly better IBS symptoms and quality of life compared to the placebo group, with no serious long-term adverse events observed.
View Article and Find Full Text PDF

Objectives: Fecal microbiota transplantation (FMT) is a promising intervention for patients with irritable bowel syndrome (IBS). The present study aimed to identify any differences in FMT response between patients with severe and moderate IBS symptoms.

Materials And Method: The study included the 164 patients who participated in our previous study, of which 96 (58.

View Article and Find Full Text PDF

Background: Fecal microbiota transplantation (FMT) interventions have recently been advocated to not succeed in every irritable bowel syndrome (IBS) patient, since the outcome of FMT varies with the IBS subset. This study investigated the factors potentially affecting FMT response using the same patient cohort used in our previous study.

Methods: This study included 109 patients who received allogenic FMT.

View Article and Find Full Text PDF
Article Synopsis
  • IBS is a common gastrointestinal disorder that affects quality of life, and while there's no effective treatment yet, fecal microbiota transplantation (FMT) shows promise.
  • A systematic review of randomized controlled trials (RCTs) identified seven studies, with four showing positive effects of FMT for IBS and three showing no benefit.
  • The success of FMT appears to depend on the donor's microbiota, suggesting the need for specific selection criteria, and more research is needed to determine the optimal dosage and administration methods for effective treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Researchers found that fecal microbiota transplantation (FMT) is a safe and effective treatment for irritable bowel syndrome (IBS), with a positive response lasting up to 1 year after treatment.
  • A follow-up study involving 77 IBS patients demonstrated significant improvements in symptoms and quality of life, with many maintaining benefits from FMT even a year later.
  • Analysis revealed that changes in the gut microbiome and specific fecal fatty acids were more pronounced after 1 year compared to the initial 3-month follow-up.
View Article and Find Full Text PDF

Background: Faecal microbiota transplantation (FMT) seems to be a promising treatment for irritable bowel syndrome (IBS) patients. In Western countries (United States and Europe), there is a female predominance in IBS. A sex difference in the response to FMT has been reported recently in IBS patients.

View Article and Find Full Text PDF

Objective: Gastric emptying measurements are mandatory in gastroparesis diagnostics, but the association between delayed emptying and symptoms is questionable. It is imperative to find biomarkers better correlated to symptom generation. Hence, we examined the association between symptom severity and gastrointestinal motility measured by wireless motility capsule.

View Article and Find Full Text PDF
Article Synopsis
  • Ultrasound is a valuable tool for measuring various physiological processes in the gastrointestinal tract, including motility and contractility in the esophagus, stomach, small bowel, and large bowel.
  • It offers a non-invasive, radiation-free method that is user-friendly and can be performed repeatedly for longitudinal studies without affecting normal gastrointestinal physiology.
  • This technology holds significant promise for both scientific research and clinical applications, potentially improving diagnostic efficiency and patient care.
View Article and Find Full Text PDF

Metabolic syndrome (MetS) is characterised by metabolic abnormalities that increase the risk of developing type 2 diabetes mellitus and cardiovascular disease. Altered levels of circulating ghrelin, several adipokines and inflammatory markers secreted from adipose tissue, such as leptin, adiponectin, tumor necrosis factor alpha, are observed in overweight and obese individuals. We assessed the effect of supplementation with low doses of a cod protein hydrolysate (CPH) on fasting and postprandial levels of acylated ghrelin, as well as fasting levels of adiponectin, leptin and inflammatory markers in subjects with MetS.

View Article and Find Full Text PDF

Irritable bowel syndrome (IBS) affects ~12% of the global population. Although the etiology of IBS is not completely understood, several factors are known to serve a pivotal role in its pathophysiology, including genetic factors, diet, the intestinal microbiota, gastrointestinal endocrine cells and low‑grade inflammation. Musashi‑1 is expressed by stem cells and their early progeny, and is used as a stem cell marker.

View Article and Find Full Text PDF
Article Synopsis
  • Irritable bowel syndrome (IBS) is linked to unexplained gastrointestinal symptoms and involves complex interactions between the brain, gut, and microbiota, prompting a multifaceted study to explore these relationships.
  • The study involves deep phenotyping of 100 IBS patients and 40 healthy controls, utilizing various assessments such as psychometric tests, biological samples, and imaging techniques over a two-year period.
  • A subgroup of IBS patients will undergo a 12-week low FODMAP dietary intervention to assess its impact on symptoms, microbiota, cognitive functions, and brain structure while employing advanced machine learning for analysis and potential biomarker identification.
View Article and Find Full Text PDF

The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate (CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a double-blind, randomized intervention study with a parallel-group design. Subjects received a daily supplement of CPH ( = 15) or placebo ( = 15).

View Article and Find Full Text PDF

A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regulation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate (CPH) on postprandial glucose metabolism in older adults.

View Article and Find Full Text PDF

Objective: Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.

View Article and Find Full Text PDF

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder of unknown aetiology for which there is no effective treatment. Although IBS does not increase mortality, it reduces the quality of life and is an economic burden to both the patients themselves and society as a whole. Peptide YY (PYY) is localized in endocrine cells located in the ileum, colon and rectum.

View Article and Find Full Text PDF

Background: Fish protein hydrolysates are suggested to contain bioactive sequences capable of affecting metabolic pathways involved in the regulation of glucose metabolism and body weight when consumed in low doses. Modulation of the appetite-regulating hormone ghrelin may explain suppression of insulin secretion and weight loss observed in previous studies with fish protein hydrolysates.

Objective: This study aimed to assess the effect of a single, low dose of cod protein hydrolysate (CPH) before a breakfast meal on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects.

View Article and Find Full Text PDF